


=>

Uploading C:\Program Files\Stnexp\Queries\10509128-amended-broad.str



ring nodes :

1 2 3 4 5 6 7 8 9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

5-6 5-7 6-9 7-8 8-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5

isolated ring systems :

containing 1 :


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10509128-amended-narrow.str



chain nodes :

1 9 10 11

ring nodes :

3 4 5 6 7 8

chain bonds :

1-8 1-9 9-10 9-11

ring bonds :

3-4 3-8 4-5 5-6 6-7 7-8

exact/norm bonds :

1-8 1-9 9-10 9-11

normalized bonds :

3-4 3-8 4-5 5-6 6-7 7-8

Match level :

1:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS 11:CLASS

Generic attributes :

1:

Saturation : Unsaturated

Number of Carbon Atoms : 7 or more  
Number of Hetero Atoms : 2 or more  
Type of Ring System : Polycyclic

Element Count :  
Node 1: Limited  
N,N2  
C,C7

L2 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 15:25:21 ON 23 JUN 2008


L1 STRUCTURE UPLOADED  
L2 STRUCTURE UPLOADED  
L4 29342 S L1 SSS FULL  
L5 194 S L2 SSS FULL SUB=L4

FILE 'CAPLUS' ENTERED AT 15:26:10 ON 23 JUN 2008

L6 17 S L5  
L7 2 S US200!-509128/APPS  
L8 1 S L6 AND L7  
L9 16 S L6 NOT L7


FILE 'REGISTRY' ENTERED AT 15:26:31 ON 23 JUN 2008

=> d l1  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l2  
L2 HAS NO ANSWERS  
L2 STR




Structure attributes must be viewed using STN Express query preparation.

=> fil caplus


=> d 18 bib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2003:796704 CAPLUS Full-text  
DN 139:307749  
TI Preparation of 7-azaindoles as inhibitors of c-Jun N-terminal kinases for  
treatment of neurodegenerative disorders  
IN Graczyk, Piotr; Numata, Hirotoshi; Khan, Afzal; Palmer, Vanessa  
PA Eisai London Research Laboratories Limited, UK  
SO PCT Int. Appl., 70 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2003082868	A1	20031009	WO 2003-GB1112	20030317
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2480317	A1	20031009	CA 2003-2480317	20030317
	AU 2003214412	A1	20031013	AU 2003-214412	20030317
	EP 1490364	A1	20041229	EP 2003-709984	20030317
	EP 1490364	B1	20070926		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1656094	A	20050817	CN 2003-812103	20030317
	JP 2005534618	T	20051117	JP 2003-580333	20030317
	AT 374200	T	20071015	AT 2003-709984	20030317
	US 20050272761	A1	20051208	US 2005-509128	20050728 <--
PRAI	GB 2002-7491	A	20020328		
	GB 2002-17330	A	20020725		
	WO 2003-GB1112	W	20030317		
OS	MARPAT 139:307749				
GI					



I



II

AB The title compds. I [wherein R = (un)substituted cyclohydrocarbyl or heterocyclyl; R' = (un)substituted alkyl, alkenyl, alkynyl, cyclohydrocarbyl, or heterocyclyl; R'' = H, (un)substituted alkyl, cyclohydrocarbyl, or heterocyclyl; X = O, S, (un)substituted NH, or alkylene; Y = a single bond, O, (un)substituted NH, or alkylene; Z = O, S, or (un)substituted NH] and pharmaceutically acceptable salts, esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents, or prodrugs thereof are prepared as inhibitors of c-Jun N-terminal kinases (JNK), and are useful for the treatment of neurodegenerative disorders related to apoptosis and/or inflammation (no data). For example, the compound II was prepared in a multi-step synthesis. II showed IC50 of 0.52  $\mu$ M against JNK3 kinase.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 19 tot bib abs hitstr

✓L9 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:619356 CAPLUS Full-text

DN 148:585883

TI Preparation of pyrrolopyridines as novel kinase inhibitors

IN Bhide, Rajeev S.; Marinier, Anne

PA ✓Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 49pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008060907	A2	20080522	WO 2007-US83850	20071107
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2006-865181P P ✓20061110

✓L9 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:43435 CAPLUS Full-text

DN 148:144656

TI Preparation of pyridinonyl PDK1 inhibitors

IN Lind, Kenneth Egnard; Cao, Kathy; Lin, Edward Yin-Shiang; Nguyen, Thinh Ba; Tangonan, Bradley T.; Erlanson, Daniel A.; Guckian, Kevin; Simmons, Robert Lowell; Lee, Wen-Cherng; Sun, Lihong; Hansen, Stig; Pathan, Nuzhat; Zhang, Lei

PA ✓Sunesis Pharmaceuticals, USA; Biogen Idec, Inc.

SO PCT Int. Appl., 311pp.

CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2008005457	A2	20080110	WO 2007-US15397	20070702
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2006-806414P	P	√20060630		
	US 2007-919057P	P	20070319		

√L9 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:88404 CAPLUS Full-text  
DN 146:184425  
TI Preparation of 1-(arylalkyl)-1H-pyrrolopyridine-2-carboxamide derivatives as VR1 type capsaicin receptor antagonists  
IN Dubois, Laurent; Evanno, Yannick; Malanda, Andre  
PA √Sanofi-Aventis, Fr.  
SO PCT Int. Appl., 57pp.  
CODEN: PIXXD2  
DT Patent  
LA French  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007010138	A2	20070125	WO 2006-FR1767	20060719
	WO 2007010138	A3	20070412		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	FR 2888848	A1	20070126	FR 2005-7804	20050722
	FR 2888848	B1	20070928		
	AU 2006271518	A1	20070125	AU 2006-271518	20060719
	CA 2615676	A1	20070125	CA 2006-2615676	20060719
	EP 1912644	A2	20080423	EP 2006-778888	20060719
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, RS

US	20080125459	A1	20080529	US	2008-970886	20080108
NO	2008000394	A	20080314	NO	2008-394	20080121
KR	2008027865	A	20080328	KR	2008-701597	20080121
PRAI	FR 2005-7804	A	20050722			
	WO 2006-FR1767	W	√20060719			

√L9 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:61234 CAPLUS Full-text

DN 146:184461

TI Preparation of as azolopyridines as inhibitors of JAK3 janus protein kinase.

IN Inoue, Takayuki; Tojo, Takashi; Morita, Masataka; Nakajima, Yutaka; Hatanaka, Keiko; Shirakami, Shohei; Sasaki, Hiroshi; Tanaka, Akira; Takahashi, Fumie; Mukoyoshi, Koichiro; Higashi, Yasuyuki; Okimoto, Akira; Hondo, Takeshi; Sawada, Hitoshi

PA √Astellas Pharma Inc., Japan

SO PCT Int. Appl., 260pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007007919	A2	20070118	WO 2006-JP314326	20060713
	WO 2007007919	A3	20070816		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	CA 2615291	A1	20070118	CA 2006-2615291	20060713
	EP 1910358	A2	20080416	EP 2006-768317	20060713
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	KR 2008026654	A	20080325	KR 2008-703506	20080213
PRAI	US 2005-698928P	P	√20050714		
	JP 2005-378858	A	20051228		
	WO 2006-JP314326	W	20060713		

√L9 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1225481 CAPLUS Full-text

DN 145:505449

TI New azabenzimidazolyl and benzimidazolyl fluorene derivatives,

compositions containing them and their use for treating cancer

IN Mailliet, Patrick; Bertin, Luc; Guyon, Thierry; Thompson, Fabienne; Ruxer, Jean-Marie; Pilorge, Fabienne; Benard, Didier; Minoux, Herve; Carrez, Chantal; Goulaouic, Helene

PA  $\sqrt$ Aventis Pharma S.A., Fr.

SO PCT Int. Appl., 307pp.  
CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2006123061	A2	20061123	WO 2006-FR1137	20060519
	WO 2006123061	A3	20070111		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	FR 2885904	A1	20061124	FR 2005-5037	20050519
	FR 2885904	B1	20070706		
	AU 2006248825	A1	20061123	AU 2006-248825	20060519
	CA 2608378	A1	20061123	CA 2006-2608378	20060519
	EP 1888579	A2	20080220	EP 2006-755509	20060519
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	IN 2007KN04384	A	20080509	IN 2007-KN4384	20071115
	MX 200714443	A	20080211	MX 2007-14443	20071116
	NO 2007006460	A	20080219	NO 2007-6460	20071214
	KR 2008025375	A	20080320	KR 2007-729644	20071218
	CN 101203518	A	20080618	CN 2006-80021973	20071219
PRAI	FR 2005-5037	A	20050519		
	WO 2006-FR1137	W	$\sqrt$ 20060519		

$\sqrt$ L9 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1124396 CAPLUS Full-text

DN 145:454998

TI Preparation of substituted pyrrolopyridines as kinase inhibitors, and their compositions and use for treatment of cancer

IN Tabart, Michel; Bacque, Eric; Halley, Frank; Ronan, Baptiste; Desmazeau, Pascal; Viviani, Fabrice; Souaille, Catherine

PA  $\sqrt$ Aventis Pharma SA, Fr.

SO Fr. Demande, 43pp.  
CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2884821	A1	20061027	FR 2005-4173	20050426
	FR 2884821	B1	20070706		
	AU 2006239105	A1	20061102	AU 2006-239105	20060426
	CA 2605744	A1	20061102	CA 2006-2605744	20060426
	WO 2006114520	A2	20061102	WO 2006-FR925	20060426
	WO 2006114520	A3	20070301		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP	1877409	A2	20080116	EP 2006-743743	20060426
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
IN	2007KN03900	A	20080201	IN 2007-KN3900	20071011
US	20080139606	A1	20080612	US 2007-870640	20071011
MX	200713084	A	20080111	MX 2007-13084	20071019
CN	101166739	A	20080423	CN 2006-80014034	20071025
KR	2008007229	A	20080117	KR 2007-724847	20071026
NO	2007005918	A	20071119	NO 2007-5918	20071116
PRAI	FR 2005-4173	A	20050426		
	WO 2006-FR925	W	20060426		

✓L9 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:333331 CAPLUS Full-text  
 DN 144:345885  
 TI Crystal structure of human phosphodiesterase 4B and molecular modeling and activity of inhibitors  
 IN Ibrahim, Prabham L.; Bremer, Ryan E.; Gillette, Samuel J.; Cho, Hanna; Nespi, Marika; Mamo, Shumeye; Zhang, Chao; Artis, Dean R.; Lee, Byunghun; Zuckerman, Rebecca L.  
 PA ✓Plexxikon, Inc., USA  
 SO PCT Int. Appl., 429 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006026754	A2	20060309	WO 2005-US31322	20050902
	WO 2006026754	A9	20060420		
	WO 2006026754	A3	20070111		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,				



NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
 ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 AU 2005279795 A1 20060309 AU 2005-279795 20050902  
 CA 2583428 A1 20060309 CA 2005-2583428 20050902  
 US 20060100218 A1 20060511 US 2005-219635 20050902  
 EP 1786813 A2 20070523 EP 2005-816059 20050902  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, YU  
 CN 101048407 A 20071003 CN 2005-80036980 20050902  
 JP 2008512380 T 20080424 JP 2007-530399 20050902  
 PRAI US 2004-607407P P 20040903  
 WO 2005-US31322 W 20050902

✓L9 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:11355 CAPLUS Full-text  
 DN 144:108300  
 TI 5-Aryl-1H-pyrrolo[2,3-b]pyridine-3-carboxylate derivatives as glycogen  
 synthase kinase-3 inhibitors, their preparation, pharmaceutical  
 compositions, and use in therapy  
 IN Berg, Stefan; Hedstroem, Johan; Hellberg, Sven; Soederman, Peter  
 PA ✓Astrazeneca AB, Swed.  
 SO PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006001754	A1	20060105	WO 2005-SE955	20050620
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1761530	A1	20070314	EP 2005-754098	20050620
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1972943	A	20070530	CN 2005-80021231	20050620
	JP 2008503575	T	20080207	JP 2007-518004	20050620
	IN 2006DN07400	A	20070615	IN 2006-DN7400	20061207
PRAI	SE 2004-1655	A	20040624		

√L9 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:1079848 CAPLUS Full-text

DN 142:56277

TI Preparation of 3-guanidinocarbonyl heterocyclic derivatives as NHE (sodium/hydrogen exchanger) inhibitors, and their pharmaceutical compositions used as cytoprotective agents

IN Carry, Jean Christophe; Mignani, Serge; Evers, Michel; Doerflinger, Gilles; Genevois, Borella Arielle; Le, Brun Alain; Martin, Jean Paul; Desmazeau, Pascal; Kleemann, Heinz Werner

PA √Aventis Pharma SA, Fr.

SO Fr. Demande, 59 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	FR 2856062	A1	20041217	FR 2003-7080	20030612
	FR 2856062	B1	20051111		
	AU 2004247350	A1	20041223	AU 2004-247350	20040528
	CA 2528382	A1	20041223	CA 2004-2528382	20040528
	WO 2004111048	A1	20041223	WO 2004-EP5764	20040528
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1641791	A1	20060405	EP 2004-739421	20040528
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004011343	A	20060711	BR 2004-11343	20040528
	JP 2006527220	T	20061130	JP 2006-515801	20040528
	US 20050014758	A1	20050120	US 2004-865454	20040610
	US 7230007	B2	20070612		
	MX 2005PA12970	A	20060525	MX 2005-PA12970	20051201
PRAI	FR 2003-7080	A	20030612		
	US 2003-497281P	P	√20030822		
	WO 2004-EP5764	W	20040528		
OS	MARPAT 142:56277				

√L9 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:996178 CAPLUS Full-text

DN 141:424170

TI Azaindole compounds as Janus kinase 3 (JAK3 kinase) inhibitors, and their preparation, intermediates, and pharmaceutical compositions

IN David, Laurent; Hansen, Peter  
 PA  $\sqrt$ Astrazeneca AB, Swed.  
 SO PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099205	A1	20041118	WO 2004-SE696	20040506
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004236146	A1	20041118	AU 2004-236146	20040506
	AU 2004236146	B2	20071213		
	CA 2523922	A1	20041118	CA 2004-2523922	20040506
	EP 1625127	A1	20060215	EP 2004-731527	20040506
	EP 1625127	B1	20070523		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004010117	A	20060523	BR 2004-10117	20040506
	CN 1784403	A	20060607	CN 2004-80012626	20040506
	JP 2006525998	T	20061116	JP 2006-508046	20040506
	AT 362932	T	20070615	AT 2004-731527	20040506
	ES 2286634	T3	20071201	ES 2004-731527	20040506
	IN 2005DN04779	A	20071207	IN 2005-DN4779	20051019
	MX 2005PA12026	A	20060203	MX 2005-PA12026	20051108
	US 20060287354	A1	20061221	US 2005-556227	20051109
PRAI	SE 2003-1372	A	20030509		
	WO 2004-SE696	W	$\sqrt$ 20040506		


$\sqrt$ L9 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:114757 CAPLUS Full-text  
 DN 139:36405  
 TI Synthesis of polyfunctional indoles and related heterocycles mediated by cesium and potassium bases  
 AU Koradin, Christopher; Dohle, Wolfgang; Rodriguez, Alain L.; Schmid, Bertram; Knochel, Paul  
 CS Department of Chemistry, Ludwig-Maximilians-Universitat Munchen, Munchen, D-81377, Germany  
 SO Tetrahedron (2003), 59(9), 1571-1587  
 CODEN: TETRAB; ISSN: 0040-4020  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 139:36405

AB A general preparation of 2-substituted indoles starting from functionalized 2-alkynylanilines has been developed. This base mediated reaction has also been used to synthesize the heterocyclic core of the marine alkaloid hinckdentine A. Furthermore the reaction was successfully adapted to the solid phase. Benzofurans and isoindolones could also be prepared with this method.

IT 543741-14-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of indoles and related heterocycles by base-catalyzed cyclization of 2-alkynylanilines in solution or solid phase)

RN 543741-14-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 2-phenyl- (CA INDEX NAME)



✓

✓L9 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:97397 CAPLUS Full-text

DN 138:153436

TI Preparation of indole-6-carboxamides and related compounds as hepatitis C viral polymerase inhibitors

IN Beaulieu, Pierre Louis; Fazal, Gulrez; Goulet, Sylvie; Kukolj, George; Poirier, Martin; Tsantrizos, Youla S.; Jolicoeur, Eric; Gillard, James; Poupert, Marc-Andre; Rancourt, Jean

PA Boehringer Ingelheim (Canada) Ltd., Can.


SO PCT Int. Appl., 336 pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2003010141	A2	20030206	WO 2002-CA1128	20020718
	WO 2003010141	A3	20030530		



✓

✓L9 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:112310 CAPLUS Full-text

DN 130:320358

TI Corticotropin-Releasing Hormone Receptor Antagonists: Framework Design and Synthesis Guided by Ligand Conformational Studies

AU Hodge, C. Nicholas; Aldrich, Paul E.; Wasserman, Zelda R.; Fernandez, Christina H.; Nemeth, Gregory A.; Arvanitis, Argyrios; Cheeseman, Robert S.; Chorvat, Robert J.; Ciganek, Engelbert; Christos, Thomas E.; Gilligan, Paul J.; Krenitsky, Paul; Scholfield, Everett; Strucely, Philip

CS Department of Chemical and Physical Sciences, DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA

SO Journal of Medicinal Chemistry (1999), 42(5), 819-832  
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB As described in the preceding paper (Arvanitis et al. J. Med. Chemical 1999, 42), anilinopyrimidines were identified as potent antagonists of corticotropin-releasing hormone-1 receptor (CRH1-R, also referred to as corticotropin-releasing factor, CRF1-R). The authors next goal was to understand the receptor-bound conformation of the antagonists and to use this information to help guide preclin. optimization of the series and to develop new leads. Since receptor structural information was not available, the authors assumed that these small, high-affinity antagonists would tend to bind in conformations at or energetically close to their global min. and that rigid analogs that maintained the important stereoelectronic features of the bound anilinopyrimidine would also bind tightly. Conformational preferences and barriers to rotation of the anilinopyrimidines were determined by semiempirical methods, and x-ray and variable-temperature NMR spectroscopy provided exptl. results that correlated well with calculated structures. Using these data, a key dihedral angle was constrained to design fused-ring analogs, substituted N- arylpyrrolopyridines, synthesis of which provided CRH1 receptor antagonists with potency equal to that of the initial congeneric leads ( $K_i = 1$  nM) and which closely matched the conformation held by the original compound, as determined by crystallog. In addition to providing a useful template for further analog synthesis, the study unequivocally determined the active conformation of the anilinopyrimidines. Theor. and spectroscopic studies, synthesis, and receptor binding data are presented.


IT 223719-80-0F

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)

(corticotropin-releasing hormone receptor antagonists in relation to framework design and synthesis of arylpyrrolopyridines guided by ligand conformational studies of anilinopyrimidines)

RN 223719-80-0 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-[2-bromo-4-(1-methylethyl)phenyl]-4,6-dimethyl- (CA INDEX NAME)



✓

✓L9 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1995:382661 CAPLUS Full-text  
 DN 122:160629  
 OREF 122:29609a,29612a  
 TI Preparation and formulation of azaindoles as ulcer inhibitors  
 IN Takahashi, Toshihiro; Horigome, Masato; Momose, Kenichi; Nagai, Shinji;  
 Sugita, Masanori; Katsuyama, Koichi; Suzuki, Chikako; Nakamaru, Koichi  
 PA Nisshin Flour Milling Co, Japan  
 SO Jpn. Kokai Tokkyo Koho, 15 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 06247966	A	19940906	JP 1993-35267	19930224
	JP 3119758	B2	20001225		
PRAI	JP 1993-35267		19930224		
OS	MARPAT 122:160629				
GI					




I ✓

✓L9 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1991:559124 CAPLUS Full-text  
 DN 115:159124  
 OREF 115:27247a,27250a  
 TI Preparation of 1-H-pyrrolopyridine-3-carboxamides as antiinflammatory agents  
 IN Scherlock, Margaret H.; Tom, Wing C.  
 PA Schering Corp., USA  
 SO U.S., 18 pp.  
 CODEN: USXXAM  
 DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5023265	A	19910611	US 1990-532304	19900601
	WO 9118902	A1	19911212	WO 1991-US3646	19910530
	W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, RO, SD, SU				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	AU 9180692	A	19911231	AU 1991-80692	19910530
PRAI	US 1990-532304	A	19900601		
	WO 1991-US3646	A	19910530		
OS	CASREACT 115:159124; MARPAT 115:159124				
GI					



I ✓

✓L9 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1976:4833 CAPLUS Full-text

DN 84:4833

OREF 84:817a,820a

TI 1H-Pyrrolo[2,3-b]pyridines. III. Novel synthetic route from 1-substituted 2-aminopyrroles

AU Brodrick, Andrew; Wibberley, D. George

CS Dep. Pharm., Univ. Aston, Birmingham, UK

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1975), (19), 1910-13  
CODEN: JCPRB4; ISSN: 0300-922X

DT Journal

LA English

OS CASREACT 84:4833

GI For diagram(s), see printed CA Issue.


AB Addnl. data considered in abstracting and indexing are available from a source cited in the original document. 1-Alkyl- and 1-aryl-2-amino-4- cyanopyrroles I, prepared in 2 steps from the condensation product of (NCCH<sub>2</sub>)<sub>2</sub> with HCO<sub>2</sub>Et, underwent cyclocondensation with 1,3-dicarbonyl compds. and their acetals, β-oxo esters, and CH<sub>2</sub>(CO<sub>2</sub>Et)<sub>2</sub> to give 1H-pyrrolo[2,3-b]pyridines. Thus, I (R = Ph) with [(MeO)CH<sub>2</sub>]<sub>2</sub>CH<sub>2</sub> and (MeO)CHCH<sub>2</sub>CO<sub>2</sub>Me gave 43 and 78% II (R = Ph, R<sub>1</sub> = H, Me, resp.). Condensation of I (R = CH<sub>2</sub>Ph, 4-MeC<sub>6</sub>H<sub>4</sub>, 3-ClC<sub>6</sub>H<sub>4</sub>, cyclohexyl) with EtOCH<sub>2</sub>C(CO<sub>2</sub>Et)<sub>2</sub> gave 75-91% 2-bis(ethoxycarbonyl)vinylaminopyrroles which on refluxing in Ph<sub>2</sub>O gave 61-74% pyrrolopyridines III. The structures of all products were determined from spectroscopic data.

IT 59661-69-7F

RL: SPN (Synthetic preparation); PREP (Preparation of)  
(preparation of)

RN 59661-69-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 4,6-dimethyl-1-phenyl- (CA INDEX NAME)



SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 15:27:04 ON 23 JUN 2008